You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 7,572,770

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,572,770

Title:	Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes
Abstract:	Substances that inhibit the action of the members of the IL-1.beta./NF-.kappa.B pathway can be used for protecting and preserving .beta.-cell mass and function in prediabetic and diabetic type 2 patients. Specifically, the present invention relates to the use of an Interleukin 1 receptor antagonist (IL-1Ra) and/or pyrrolidinedithiocarbamate (PDTC) for the treatment or prophylaxis of type 2 diabetes, as well as a method for the treatment of type 2 diabetes.
Inventor(s):	Donath; Marc (Adliswil, CH)
Assignee:	University of Zurich (Zurich, CH)
Application Number:	10/517,450
Patent Claims:	1. A method of treating type 2 diabetes or prophylactically suppressing type 2 diabetes in a mammal predisposed to type 2 diabetes, the method comprising administering to a mammal in need thereof a medicament comprising a sufficient amount of anakinra. 2. The method according to claim 1, wherein the medicament is adapted for parenteral administration. 3. The method according to claim 2, wherein anakinra is administered to the mammal in a dose of 0.1 to 1000 mg of anakinra per kg of body weight. 4. The method according to claim 1, wherein the medicament further comprises pyrrolidinedithiocarbamate (PDTC). 5. The method according to claim 4, wherein the medicament is adapted for parenteral administration. 6. The method according to claim 5, wherein the anakinra is administered to the mammal in a dose of 0.1 to 1000 mg of anakinra per kg of body weight. 7. The method according to claim 6, wherein the PDTC is administered to the mammal in a dose of 0.1 to 1000 mg of PDTC per kg of body weight. 8. A method of treating type 2 diabetes, the method comprising administering to a mammal in need thereof a dose of 0.1 to 1000 mg of anakinra per kg of body weight. 9. The method according to claim 8, wherein the medicament is administered via parenteral administration. 10. The method according to claim 8, wherein the medicament further comprises pyrrolidinedithiocarbamate (PDTC). 11. The method according to claim 10, wherein the medicament is administered by parenteral administration. 12. The method according to claim 11, wherein the PDTC is administered to the mammal in a dose of 0.1 to 1000 mg of PDTC per kg of body weight.

Details for Patent 7,572,770

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	KINERET	anakinra	Injection	103950	11/14/2001	⤷ Try a Trial	2039-03-29
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.